Skip to content

H.R. 5160 · 119th Congress (2025–2027)

Stem Cell Therapeutic and Research Reauthorization Act of 2025

This bill reauthorizes through FY2031 and revises programs that help patients receive transplants of bone marrow or umbilical cord blood from biologically unrelated donors. These programs are administered by the Health Resources and Services Administration (HRSA).

The bill reauthorizes the C.W. Bill Young Cell Transplantation Program. This program supports transplantation of bone marrow and cord blood by increasing the quantities of donations, providing processes for matching and distributing donated materials to patients, and providing related information and research.

Also, the bill reauthorizes and revises the National Cord Blood Inventory program, through which HRSA contracts with qualified cord blood banks to collect and maintain a supply of high-quality units for transplantation through the C.W. Bill Young Cell Transplantation Program. The bill amends the inventory program by (1) changing the inventory goal from 150,000 units to a sufficient supply as determined by HRSA, (2) requiring HRSA to manage the size and composition of the inventory to maximize clinical utility and efficiency, and (3) defining high quality cord blood unit to mean a unit meeting current industry standards and the requirements of the Food and Drug Administration.

Show official title

To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes.

Passed House

This bill’s path

319 days after it was introduced

This is H.R. 5160’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced10 months

  2. Passed House

  3. Passed Senate

  4. Sent to President

  5. Signed into law

Sponsor
Rep. Christopher H. Smith (R-NJ-4)
Cosponsors
21 cosponsors

5 original · 16 later

10 R · 11 D

  1. Rep. Gus M. Bilirakis (R-FL-12)· Original · Sep 4, 2025
  2. Rep. Kweisi Mfume (D-MD-7)· Original · Sep 4, 2025
  3. Rep. Doris O. Matsui (D-CA-7)· Original · Sep 4, 2025
  4. Rep. Chellie Pingree (D-ME-1)· Original · Sep 4, 2025
  5. Rep. Claudia Tenney (R-NY-24)· Original · Sep 4, 2025
  6. Rep. Debbie Dingell (D-MI-6)· Later · Feb 4, 2026
  7. Rep. Michelle Fischbach (R-MN-7)· Later · Feb 4, 2026
  8. Rep. Robert B. Aderholt (R-AL-4)· Later · Feb 10, 2026
  9. Rep. Josh Gottheimer (D-NJ-5)· Later · Feb 10, 2026
  10. Rep. Kathy Castor (D-FL-14)· Later · Apr 2, 2026
  11. Rep. Andrew R. Garbarino (R-NY-2)· Later · Apr 2, 2026
  12. Rep. Nicole Malliotakis (R-NY-11)· Later · Apr 2, 2026
  13. Del. Eleanor Holmes Norton (D-DC)· Later · Apr 2, 2026
  14. Rep. Cliff Bentz (R-OR-2)· Later · Apr 27, 2026
  15. Rep. Nanette Diaz Barragán (D-CA-44)· Later · Apr 27, 2026
  16. Rep. Brad Finstad (R-MN-1)· Later · Apr 30, 2026
  17. Rep. Kelly Morrison (D-MN-3)· Later · Apr 30, 2026
  18. Rep. Michael Lawler (R-NY-17)· Later · May 21, 2026
  19. Rep. Eugene Simon Vindman (D-VA-7)· Later · May 21, 2026
  20. Rep. Sharice Davids (D-KS-3)· Later · May 29, 2026
  21. Rep. Brian K. Fitzpatrick (R-PA-1)· Later · May 29, 2026
Policy area
Health
Subjects
  • Biological and life sciences
  • Blood and blood diseases
  • Cell biology and embryology
  • Health programs administration and funding
  • Organ and tissue donation and transplantation

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Referred to Health

    Referred to the Subcommittee on Health.

    Sources
  2. Introduced in House

    Document: Introduced in House

    Sources
  3. ▸ 6 committee actions · Sep 4, 2025 – Jul 2, 2026
    1. Referred to committee

      Referred to the House Committee on Energy and Commerce.

      Sources
    2. Subcommittee markup session held

      Subcommittee Consideration and Mark-up Session Held

      Sources
    3. Forwarded by subcommittee

      Forwarded by Subcommittee to Full Committee by Voice Vote.

      Sources
    4. Markup session held

      Committee Consideration and Mark-up Session Held

      Sources
    5. Ordered reported

      Ordered to be Reported (Amended) by the Yeas and Nays: 48 - 0.

      Sources
    6. Reported by committee

      Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-724.

      Sources
  4. Latest

    Passed House

    Congressional Record H4642

    On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.

    The House passed the bill as amended.

    Document: Engrossed in House

    Sources

Committees

  1. HouseEnergy and CommerceReferred Sep 4, 2025 · Markup May 21, 2026 · Reported Jul 2, 2026H. Rept. 119-724
    1. H. Rept. 119-724 · Jul 2, 2026 · Stem Cell Therapeutic and Research Reauthorization Act of 2025
  2. HouseHealthReferred Sep 4, 2025 · Markup May 13, 2026 · Reported May 13, 2026
    1. May 13, 2026 · Markup

Floor record

i

Explicit consideration evidence: the measure’s bill-status citation matched a GovInfo title, headline, or first paragraph. Incidental mentions are not listed.

  1. Jul 20, 2026 · House · Considered under suspension of the rulesCongressional Record H4642–H4643

    Stem Cell Therapeutic and Research Reauthorization Act of 2025

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in House
Reported in House
Engrossed in House
Placed on Calendar Senate
Titles (2)
  1. Stem Cell Therapeutic and Research Reauthorization Act of 2025

    Display title, Short title · Placed on Calendar Senate, Engrossed in House, Reported in House, Introduced in House

  2. To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes.

    Official title · Engrossed in House, Introduced in House